| Description | Imeglimin hydrochloride (EMD 387008 hydrochloride) prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. |
| In vitro | Imeglimin dramatically decreased reactive oxygen species production, inhibiting specifically reverse electron transfer through complex I. Imeglimin prevents hyperglycemia-induced cell death in HMEC-1 through inhibition of PTP opening without inhibiting mitochondrial respiration nor affecting cellular energy status[1]. |
| Synonyms | EMD 387008 hydrochloride, (6R)-1,6-二氢-N2,N2,6-三甲基-1,3,5-三嗪-2,4-二胺盐酸盐 |
| molecular weight | 191.66 |
| Molecular formula | C6H14ClN5 |
| CAS | 775351-61-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (286.97 mM) |
| References | 1. Detaille D , Vial G , Borel A L , et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration[J]. Cell death discovery, 2016, 2:15072. 2. Vuylsteke V , Chastain L M , Maggu G A , et al. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes[J]. Drugs in R&D, 2015, 15(3):227-232. |